Discounted Cash Flow (DCF) Analysis Levered
Dermapharm Holding SE (DMP.DE)
47.22 €
+0.18 (+0.38%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | 467.12 | 572.42 | 700.88 | 793.83 | 942.91 | 1,124.49 | 1,341.02 | 1,599.26 | 1,907.23 | 2,274.49 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | 86.74 | 159.13 | 100.61 | 131.10 | 250.37 | 233.42 | 278.37 | 331.97 | 395.90 | 472.14 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -74.71 | -25.97 | -46.44 | -40.80 | -61.20 | -87.23 | -104.03 | -124.07 | -147.96 | -176.45 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | 12.02 | 133.15 | 54.17 | 90.30 | 189.16 | 146.19 | 174.34 | 207.91 | 247.94 | 295.69 |
Weighted Average Cost Of Capital
Share price | $ 47.22 |
---|---|
Beta | 1.187 |
Diluted Shares Outstanding | 53.84 |
Cost of Debt | |
Tax Rate | 28.46 |
After-tax Cost of Debt | 1.09% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 9.302 |
Total Debt | 580.30 |
Total Equity | 2,542.32 |
Total Capital | 3,122.63 |
Debt Weighting | 18.58 |
Equity Weighting | 81.42 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | 467.12 | 572.42 | 700.88 | 793.83 | 942.91 | 1,124.49 | 1,341.02 | 1,599.26 | 1,907.23 | 2,274.49 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | 86.74 | 159.13 | 100.61 | 131.10 | 250.37 | 233.42 | 278.37 | 331.97 | 395.90 | 472.14 |
Capital Expenditure | -74.71 | -25.97 | -46.44 | -40.80 | -61.20 | -87.23 | -104.03 | -124.07 | -147.96 | -176.45 |
Free Cash Flow | 12.02 | 133.15 | 54.17 | 90.30 | 189.16 | 146.19 | 174.34 | 207.91 | 247.94 | 295.69 |
WACC | ||||||||||
PV LFCF | 135.63 | 150.08 | 166.06 | 183.74 | 203.30 | |||||
SUM PV LFCF | 838.81 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 7.78 |
Free cash flow (t + 1) | 301.60 |
Terminal Value | 5,218.08 |
Present Value of Terminal Value | 3,587.73 |
Intrinsic Value
Enterprise Value | 4,426.54 |
---|---|
Net Debt | 418.87 |
Equity Value | 4,007.67 |
Shares Outstanding | 53.84 |
Equity Value Per Share | 74.44 |